Estrella Immunopharma Inc.
Ownership
Ownership Structure
Who owns Estrella Immunopharma Inc. (ESLA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 33.0% of the shares are freely tradable; institutional investors hold 12.2%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.53 | 4,099,000 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 0.89 | 382,469 | +0.0 | 03/31/2026 |
| Wells Fargo & Co | 0.61 | 264,388 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 0.37 | 157,485 | +43.4 | 03/31/2026 |
| Vanguard Fiduciary Trust Co | 0.15 | 64,921 | +0.0 | 03/31/2026 |
| Renaissance Technologies Corp | 0.15 | 62,795 | -48.7 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 0.62 | 268,605 | +0.0 | 07/31/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.34 | 148,247 | +0.0 | 07/31/2026 |
| Fidelity Extended Market Index | 0.19 | 80,878 | -0.2 | 07/31/2026 |
| iShares Micro-Cap ETF | 0.11 | 49,333 | -1.9 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Liu Cheng | CEO | 397,437 | 209,052 $ | Aug 25, 2026 | direct |
| Xu Jiandong | Chief Financial Officer | 365,488 | 192,247 $ | Aug 18, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | Liu Cheng | CEO | Other | 100,000 | 0.815 | 81,500 |
| Aug 18, 2026 | Xu Jiandong | Chief Financial Officer | Other | 100,000 | 0.815 | 81,500 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.